Molecular Partners announced its unaudited financial results for 2018 and corporate highlights for the fourth quarter 2018. The fourth quarter was marked by positive phase 3 efficacy data presented for abicipar as well as the initiation of a strategic collaboration with Amgen in the field of immuno-oncology, two key milestones for the company.
Category Archives: Uncategorized
Company highlights recent progress on clinical DARPin® compounds, its oncology research strategy and to discuss the strategic collaboration with Amgen on MP0310.
Molecular Partners and Amgen announced a collaboration and license agreement for the clinical development and commercialization of MP0310 (FAP x 4-1BB). MP0310 is a preclinical molecule designed to locally activate immune cells in the tumor by binding to FAP on tumor stromal cells (localizer) and co-stimulating T cells via 4-1BB (immune modulator).
Molecular Partners announces the continued progress of its pipeline of proprietary therapeutic product candidates in oncology and immuno-oncology, as well as in ophthalmology together with its partner Allergan on the company’s R&D Day in New York.
Molecular Partners will present new data on its immuno-oncology pipeline at upcoming scientific conferences.
Molecular Partners published its Interim Management Statement for the period ending September 30, 2018, highlighting positive phase 3 efficacy data for abicipar, the ongoing clinical trials for MP0250 in oncology as well as further advancement of the immuno-oncology pipeline of the company.
Phase 3 safety and efficacy data of abicipar in patients with neovascular Age-related Macular Degeneration (nAMD) were presented at the American Academy of Ophthalmology (AAO) conference in Chicago. These data underline that abicipar has the potential to become the first fixed 12-week anti-VEGF therapeutic.
Molecular Partners announces its unaudited financial results for the first half-year 2018, including promising updated data on the phase 2 trial of its lead oncology asset MP0250 and the positive phase 3 topline data for abicipar, as announced on July 19, 2018 by the company’s strategic partner Allergan.
Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials for Abicipar pegol 8 and 12-week Regimens for the Treatment in Patients with Neovascular Age-Related Macular Degeneration
Molecular Partners announces the appointment of PamelaTrail as Chief Scientific Officer and Michael Stumpp as Chief Operating Officer of the company.